Update to COVID-19 Monoclonal Antibody (mAb) Ordering Process for All Sites
September 3, 2021
Monoclonal Antibody Therapeutic Updates
The COVID-19 pandemic is rapidly evolving, and new updates are issued frequently. To view a full list of HHS/ASPR’s updates related to COVID-19 monoclonal antibody therapeutics, please see our
full list of updates.
The recent increase in the prevalence of the Delta variant of COVID-19 has caused a substantial surge in the utilization of monoclonal antibody drugs. It remains the goal of the federal government to ensure continued availability of these drugs for current and future patients. As such, HHS is immediately implementing the following changes to help promote optimal and equitable use of the available supply of monoclonal antibodies while we continue efforts to procure additional product:
- Limiting immediate orders and shipment only to administration sites with HHSProtect accounts and current utilization reporting
- Reviewing all orders for alignment with utilization, currently estimated at 70% of orders
Please note that this is a temporary change. We will continue to monitor product utilization rates, variant prevalence, and overall availability of monoclonal antibody therapeutics to determine when we will shift back to the normal direct ordering process.
Should monoclonal antibody administration sites have questions regarding this update in ordering and distribution procedures or if administration sites need assistance establishing an HHSProtect account, please
email the Federal COVID-19 Response Team at COVID19therapeutics@hhs.gov.